Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15162 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Norman Aiad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Engdahl Family Chair for Heart Failure Research and in part by the National Institutes of Health, University of Minnesota.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background and Aims Patients with heart failure with preserved ejection fraction (HFpEF) tend to have low resting and exercise heart rates. Phosphodiesterase-3 (PDE-3) inhibitors improve heart rates, haemodynamics and symptoms in patients with HFpEF. Cilostazol is an oral PDE-3 inhibitor used in peripheral artery disease. This study thought to evaluate the short-term effects of cilostazol on health status, N-terminal brain natriuretic peptide (NT-proBNP) levels and mechanisms of action.
Methods
The effect of cilostazol was evaluated in 23 patients with HFpEF in a randomized placebo controlled multiple crossover trial (CLIP-HFpEF). Participants received placebo or cilostazol for 1 week followed by three crossovers to the alternate assignment at weeks 2, 3 and 4. The primary endpoint was the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score obtained at the end of each treatment period. NT-proBNP was the secondary endpoint. In an exploratory mechanistic analysis, pulmonary artery (PA) pressures and heart rates were followed amongst the five participants with implanted pressure monitors.
Results
Cilostazol improved the KCCQ score by 4.8 points (95% confidence interval, 2.0–7.7, P = 0.003). NT-proBNP levels were 448 (154–1056) pg/mL on placebo and 375 (68–974) pg/mL on cilostazol (P = 0.006). In patients with PA pressure monitors, diastolic pressure was 20.5 (18.7–23.0) mmHg on placebo and 18.0 (17.0–20.0) mmHg on cilostazol, an effect linked to higher heart rates (P < 0.001).
Conclusions
Amongst patients with HFpEF, short-term treatment with cilostazol leads to improvements in health status and NT-proBNP when compared with placebo. These effects are likely conveyed by a heart rate-dependent reduction in cardiac filling pressures. Trial Registration ClinicalTrials.gov Identifier: NCT05126836.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
- Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA.
- Cardiovascular Research Institute Basel, Basel, Switzerland.
- Department of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA.
ORCID-Profile: Norman Aiad
Förderung
- Engdahl Family Chair for Heart Failure Research and in part by the National Institutes of Health
- University of Minnesota
Zitieren
APA
Aiad, N., du Fay de Lavallaz, J., Zhang, M. J., Chaikijurajai, T., Ye, B., Nijjar, P. S., Lahiri, J. A., Martin, C. M., Alexy, T., & Meyer, M. (2025). Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.15162
Vancouver
Aiad N, du Fay de Lavallaz J, Zhang MJ, Chaikijurajai T, Ye B, Nijjar PS, et al. Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial. ESC Heart Failure. 2025. doi:10.1002/ehf2.15162
BibTeX
@article{Aiad2025,
author = {Aiad, Norman and du Fay de Lavallaz, Jeanne and Zhang, Michael J and Chaikijurajai, Thanat and Ye, Bo and Nijjar, Prabhjot S and Lahiri, Julie A and Martin, Cindy M and Alexy, Tamas and Meyer, Markus},
title = {Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15162}
}
EUVIMED